936716-41-5

Upstream product

• 824390-04-7 4-(2-(trifluoromethyl)phenoxy)piperidine 
• 10191-60-3 dimethyl N-cyanodithioiminocarbonate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 444-30-4 2-(trifluoromethyl)phenol 
• 921605-76-7 tert-butyl 4-[2-(trifluoromethyl)phenoxy]-piperidine-1-carboxylate 

Downstream Products

• 936716-42-6 4-amino-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-1,3-thiazole-5-carboxamide 
• 1085784-06-0 methyl 6-(7-oxo-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-6,7-dihydro[1,3]thiazolo[4,5-d]pyrimidin-5-yl)nicotinate 
• 1085784-14-0 5-({[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino}methyl)-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}[1,3]thiazolo[4,5-d]pyrimidin-7(6H)-one 
• 1085784-05-9 methyl 6-({[(4-amino-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-1,3-thiazol-5-yl)carbonyl]amino}carbonyl)nicotinate 

Relevant academic research and scientific papers

Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: From systemic to liver-targeting inhibitors

Optimization of a lead thiazole amide MF-152 led to the identification of potent bicyclic heteroaryl SCD1 inhibitors with good mouse pharmacokinetic profiles. In a view to target the liver for efficacy and to avoid SCD1 inhibition in the skin and eyes where adverse effects were previously observed in rodents, representative systemically-distributed SCD1 inhibitors were converted into liver-targeting SCD1 inhibitors.

BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Bicyclic heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis